OTCMKTS:UCBJF

UCB Stock Forecast, Price & News

$96.65
0.00 (0.00 %)
(As of 06/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$96.65
$96.65
50-Day Range
$93.00
$98.00
52-Week Range
$93.00
$131.00
VolumeN/A
Average Volume187 shs
Market Capitalization$18.27 billion
P/E Ratio15.79
Dividend YieldN/A
Beta0.56
30 days | 90 days | 365 days | Advanced Chart
Receive UCBJF News and Ratings via Email

Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter.


UCB logo

About UCB

UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, nayzilam, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; bimekizumab for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition , the company is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis immune-mediated necrotizing myopathy; staccato alprazolam to treat active epileptic seizure; and UCB0107 to treat tauopathies and progressive supranuclear palsy. Further, it engages in contract manufacturing activities. The company has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was founded in 1928 and is headquartered in Brussels, Belgium.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

0.71 out of 5 stars

Medical Sector

1320th out of 2,102 stocks

Pharmaceutical Preparations Industry

593rd out of 832 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











UCB (OTCMKTS:UCBJF) Frequently Asked Questions

Is UCB a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for UCB in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" UCB stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in UCBJF, but not buy additional shares or sell existing shares.
View analyst ratings for UCB
or view top-rated stocks.

What stocks does MarketBeat like better than UCB?

Wall Street analysts have given UCB a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but UCB wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting UCB?

UCB saw a decrease in short interest in May. As of May 28th, there was short interest totaling 433,400 shares, a decrease of 17.3% from the May 13th total of 523,900 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 4,334.0 days.
View UCB's Short Interest
.

When is UCB's next earnings date?

UCB is scheduled to release its next quarterly earnings announcement on Thursday, June 17th 2021.
View our earnings forecast for UCB
.

How has UCB's stock price been impacted by COVID-19?

UCB's stock was trading at $97.20 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, UCBJF shares have decreased by 0.6% and is now trading at $96.65.
View which stocks have been most impacted by COVID-19
.

Who are UCB's key executives?

UCB's management team includes the following people:
  • Mr. Jean-Christophe Tellier, CEO & Exec. Director (Age 62)
  • Ms. Kirsten Lund-Jurgensen, Exec. VP of Supply & Technology Solutions (Age 62)
  • Dr. Dhavalkumar D. Patel Ph.D., M.D., Exec. VP & Chief Scientific Officer (Age 60)
  • Mr. William J. Silbey, Exec. VP & Gen. Counsel (Age 62)
  • Mr. Jean-Luc Fleurial, Exec. VP & Chief HR Officer (Age 56)
  • Prof. Iris Löw-Friedrich, Chief Medical Officer, Head of Devel. & Medical Patient Value Practices and Exec. VP (Age 61)
  • Mr. Emmanuel Caeymaex, Exec. VP of Immunology Solutions & Head of US (Age 52)
  • Mr. Charl Van Zyl, Exec. VP of Neurology Solutions & Head of EU/International (Age 54)
  • Ms. Sandrine Dufour, Exec. VP & CFO (Age 54)
  • Ms. Caroline Vancoillie, Chief Accounting Officer & CFO of Patient Value Functions

Who are some of UCB's key competitors?

What is UCB's stock symbol?

UCB trades on the OTCMKTS under the ticker symbol "UCBJF."

How do I buy shares of UCB?

Shares of UCBJF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UCB's stock price today?

One share of UCBJF stock can currently be purchased for approximately $96.65.

How much money does UCB make?

UCB has a market capitalization of $18.27 billion and generates $6.11 billion in revenue each year. The company earns $836.16 million in net income (profit) each year or $6.12 on an earnings per share basis.

How many employees does UCB have?

UCB employs 8,371 workers across the globe.

When was UCB founded?

UCB was founded in 1928.

What is UCB's official website?

The official website for UCB is www.ucb.com.

Where are UCB's headquarters?

UCB is headquartered at Allee de la Recherche 60, Brussels C9, 1070.

How can I contact UCB?

UCB's mailing address is Allee de la Recherche 60, Brussels C9, 1070. The company can be reached via phone at 32-2559-9999 or via email at [email protected]


This page was last updated on 6/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.